Skip to main content

Table 7 Determinants and effects of institutional strategies on the costs of medications requested in lawsuits from January 2003 to December 2015

From: Institutional strategies as a mechanism to rationalize the negative effects of the judicialization of access to medicine in Brazil

VariablesBivariate regressionMultivariable regression3
β1 (IC 95%)2pβ1 (IC 95%)2p
Plaintiffs’ characteristics
 Age (years)0.05 (−0.10; 0.21)0.517  
 Sex    
  Male1.00   
  Female−0.09 (− 0.38; 0.18)0.502  
 Income (US$)0.45 (0.23; 0.66)<  0.0010.41 (0.22–0.61)<  0.001
Characteristics of the lawsuits
 Quantity of medicines0.13 (0.07; 0.19)<  0.0010.17 (0.12–0.23)<  0.001
Origin of the prescriptions
 Prescribed by a SUS clinician1.00   
 Prescribed by a private system clinician0.84 (0.42; 1.27)<  0.001  
Diseases
 Certain infectious and parasitic diseases−0.84 (−2.29; 0.60)0.252  
 Neoplasms1.40 (0.18; 2.62)0.024  
 Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism−1.84 (−3.45; −0.23)0.025  
 Endocrine, nutritional and metabolic diseases−0.25 (− 0.80; 0.01)0.057  
 Mental and behavioural disorders0.07 (−0.33; 0.46)0.740  
 Diseases of the nervous system−0.26 (− 0.64; − 0.12)0.178  
 Diseases of the eye and adnexa−0.55 (1.34; 0.24)0.172  
 Diseases of the circulatory system−0.21 (− 0.56; 0.13)0.220  
 Diseases of the respiratory system−0.04 (− 0.83; 00.75)0.917  
 Diseases of the digestive system0.19 (−0.43; 0.83)0.543  
 Diseases of the musculoskeletal system and connective tissue−2.42 (−4.99; 0.15)0.066  
 Interventions−0.29 (−0.92; 0.32)0.348  
DAMNP4
 Before deployment1.00 1.00 
 After deployment−0.36 (−0.51; − 0.20)<  0.001− 0.20 (− 0.37; − 0.10)<  0.001
CATS5
 Before deployment1.00 1.00 
 After deployment−0.48 (− 066; − 0.31)<  0.001−0.25 (− 0.30; − 0.10)<  0.001
 R2: 0.140
R2 adjusted: 0.132
  1. 1Regression coefficient; 2Confidence interval of 95%;3Model adjusted by sex, age, origin of the prescription, quantity of medicines, neoplastic diseases, blood diseases, endocrine diseases, diseases of the osteomuscular system and strategies (DAMNP e CATS); 4Period before the deployment of 5Department of Assessment of Non-Standardized Medicines: 2003–2005/Period after the deployment of Department of Assessment of Non-Standardized Medicines: 2007–2015; 5Period before deployment of Technical Chamber of Health Assessment: 2003–2008/ Period after deployment of Technical Chamber of Health Assessment: 2010–2015
\